Protalix BioTherapeutics (Protalix BioTherapeutics) EPS (Basic) : $0.11 (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Protalix BioTherapeutics EPS (Basic)?

Protalix BioTherapeutics's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $-0.10. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.11.

Protalix BioTherapeutics's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.10. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.02.

Protalix BioTherapeutics's EPS without NRI for the three months ended in Dec. 2023 was $-0.10. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was 0.02.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Protalix BioTherapeutics's highest 3-Year average EPS without NRI Growth Rate was 59.70% per year. The lowest was -54.60% per year. And the median was 11.45% per year.

Protalix BioTherapeutics EPS (Basic) Historical Data

The historical data trend for Protalix BioTherapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protalix BioTherapeutics EPS (Basic) Chart

Protalix BioTherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-1.23

-0.22

-0.62

-0.31

0.12

Protalix BioTherapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															-0.07	-0.05	0.29	-0.03	-0.10

Protalix BioTherapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Protalix BioTherapeutics's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(8.312	-	0)	/	67.513
	=	0.12

Protalix BioTherapeutics's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-6.044	-	0)	/	72.616
	=	-0.08

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.11

Protalix BioTherapeutics (AMEX:PLX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Protalix BioTherapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Protalix BioTherapeutics (Protalix BioTherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (AMEX:PLX) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

PBDA:Germany

Address

2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601

Website

https://www.protalix.com

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.

Executives

Dror Bashan	director, officer: President and CEO	2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 L3 20100
Eliot Forster	director	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Aharon Schwartz	director	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100
Zvi Shmuel Ben	director	2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 2161401
Dexcel Pharma Technologies Ltd.	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 3060000
Dan Oren	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 30600000
Eyal Rubin	officer: Sr. VP and CFO	C/O BRAINSTORM CELL THERAPEUTICS INC.,, 3 UNIVERSITY PLAZA DRIVE, STE 320, HACKENSACK NJ 07601
Yaron Naos	officer: Sr. VP, Operations	2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 20100
Yael Hayon	officer: Vice President, R&D	2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 2161401
Zeev Bronfeld	director	6 URI STREET, TEL AVIV L3 64954
Amos Bar-shalev	director	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100
David Granot	director	6225 NEIL ROAD, RENO NV 89511
Pol F Boudes	director	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Gwen A Melincoff	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Moshe Manor	officer: President & CEO	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100